<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812643</url>
  </required_header>
  <id_info>
    <org_study_id>D1250C00032</org_study_id>
    <nct_id>NCT00812643</nct_id>
  </id_info>
  <brief_title>Excretion of Radiolabelled AZD0837</brief_title>
  <official_title>An Open, Single Centre Pharmacokinetic (Phase 1) Study of the Biliary Excretion of AZD0837 and Metabolites Following a Single Dose of [3H] AZD0837 Given in the Duodenum Via a Loc-I-Gut Catheter to Young Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an explorative study and the scientific question to be investigated in this study is
      if AZD0837 and/or its metabolites AR-H069927XX and AR-H067637XX and other unknown metabolites
      are excreted into the bile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amounts of total radioactivity excreted in bile. Metabolic profile of AZD0837 excreted in bile and identification of previously unknown metabolites and the amounts of AZD0837, AR-H069927XX and AR-H067637XX in bile.</measure>
    <time_frame>Frequent sampling through a Loc-I-Gut catheter for up to 3 hours post dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK variables of AZD0837, AR-H069927XX, and AR-H067637XX.</measure>
    <time_frame>Frequent sampling during 24 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, physical examination, safety laboratory variables, blood pressure, pulse and electrocardiography.</measure>
    <time_frame>Some of the safety variables will be followed at each visit, some less frequent.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0837</intervention_name>
    <description>Oral solution, dosing through the Loc-I-Gut catheter, single dose</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg
             inclusive

        Exclusion Criteria:

          -  Significant illness, trauma or surgical procedures.

          -  Clinically significant laboratory abnormalities.

          -  Clinically significant medical history.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Knutson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inst för Kirurgiska VetenskaperUppsala Universitet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <last_update_submitted>March 10, 2009</last_update_submitted>
  <last_update_submitted_qc>March 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Karin Wåhlander, MSD</name_title>
    <organization>AstraZeneca R&amp;D Mölndal</organization>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

